Inspira Technologies OXY B.H.N. Ltd. has received the first ever U.S. Patent approval for their orbiting blood oxygenation delivery system, VORTX™, which is a core technology of their revolutionary INSPIRA™ ART500 device. This innovation has 16 novel claims. Unlike existing fiber technologies used for blood oxygenation, which can cause damage to the patient’s blood cells, the VORTX™ system is designed to oxygenate blood without fiber membranes. CEO Dagi Ben-Noon believes that this advancement has the potential to revolutionize the medical landscape.
The INSPIRA ART500 device is aimed at targeting the $19 billion mechanical ventilation market, providing an alternative to invasive mechanical ventilation systems by empowering breathing in awake patients. Equipped with the HYLA blood sensor, it continuously measures blood parameters in real-time and delivers needed oxygen volume directly into the blood. This technology potentially allows for real-time detection of changes in a patient’s condition, providing valuable data to physicians.
Inspira Technologies is focused on developing innovative medical technology for respiratory treatment, with the goal of rebalancing patient oxygen saturation levels. While not yet tested or approved for human use, the company’s breakthrough Augmented Respiration Technology (INSPIRA ART) aims to reduce the need for risky and costly mechanical ventilation systems that require intubation and medically induced coma.
This patent approval marks a significant milestone for Inspira Technologies, showcasing the potential impact of their technology on blood oxygenation and patient care. As the company continues to advance in the field of medical technology, they are committed to further developing their innovative solutions for respiratory treatment.
Source
Photo credit finance.yahoo.com
